![]() ![]() We understand the dynamics impacting the pace of growth of TEPEZZA, and we are executing on our strategy to address them, including a more significant expansion of our TEPEZZA field force and implementing initiatives to drive further penetration. Importantly, our long-term outlook for TEPEZZA has not changed and we continue to estimate that our three key growth drivers TEPEZZA, KRYSTEXXA and UPLIZNA can generate aggregate global peak annual net sales of greater than $5.5 billion. “We are revising our full-year guidance to reflect our expectation for TEPEZZA full-year net sales percentage growth in the high-teens and reflect recent generic competition in our inflammation segment. “We were also pleased to receive FDA approval of our expanded KRYSTEXXA label in July, to include co-administration of KRYSTEXXA with methotrexate, which will enable many more patients to benefit from this important medicine.” ![]() ![]() “Double-digit net sales growth in our orphan segment drove our second-quarter performance, with very strong growth of KRYSTEXXA and an increasing contribution from UPLIZNA,” said Tim Walbert, chairman, president and chief executive officer, Horizon. 3, 2022- Horizon Therapeutics plc (Nasdaq: HZNP) today announced second-quarter 2022 financial results and revised its full-year 2022 net sales and adjusted EBITDA guidance. UPLIZNA ® (inebilizumab) Approved by European Commission for the Treatment of Adult Patients with NMOSD Commercial Launch Underway in Germany -ĭUBLIN-(BUSINESS WIRE)-Aug. FDA Approval for Expanded KRYSTEXXA Label to Include Co-Administration with Methotrexate Based on Positive MIRROR Results That Demonstrated Improved and Sustained Patient Response. Full-Year 2022 TEPEZZA Net Sales Percentage Growth in the High-Teens. Full-Year 2022 Adjusted EBITDA Guidance of $1.30 Billion to $1.35 Billion. Full-Year 2022 Net Sales Guidance of $3.53 Billion to $3.60 Billion, Reflecting Revised Net Sales Expectations for TEPEZZA and Inflammation Segment. Cash Position of $1.89 Billion as of J. KRYSTEXXA ® (pegloticase injection) Net Sales of $167.8 Million. TEPEZZA ® (teprotumumab-trbw) Net Sales of $479.8 Million. GAAP Net Income of $61.0 Million Adjusted EBITDA of $306.6 Million. Net Sales of $876.4 Million Orphan Segment Net Sales Increased 13% to $841.3 Million. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |